Skip to main content

BRIEF-Amgen submits supplemental biologics license application for BLINCYTO

* Amgen says submits supplemental Biologics license application for Blincyto in relapsed or refractory b-cell precursor acute lymphoblastic leukemia Source text for Eikon: Further company coverage:
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.